Heading its list for filling its FNC (Future Naval Capability) gaps in Fiscal 2007 are oxygen-carrying blood substitutes
PolyHeme, Northfield Laboratories' hemoglobin-based oxygen-carrying blood substitute
, holds promise for Jehovah's Witnesses who do not accept blood transfusions based on religious convictions.
This opportunity helps underscore what a significant need the continued development of a safe, non-toxic blood substitute
is for the global marketplace.
Before freeze-dried blood substitutes
can be tried in humans, however, he says the toxicology of trehalose must be tested.
HemoBioTech is working on the development and commercialization of HemoTech, a novel human blood substitute
technology exclusively licensed from Texas Tech University Health Sciences Center.
But lately I haven't heard anything--anything-- about using perfluorocarbons as a circulating blood substitute
The article, "Fresh Hope For Emergency Blood Substitutes
" concerns HemoBioTech's lead product, HemoTech, and describes the technology platform's potential ability to become a safe, inexpensive, oxygen-carrying human blood substitute
OTCBB:SYBD) today announced that The Body, the first of the three-part Discovery Channel documentary 2057, will highlight the future potential of fluorocarbon technology as an oxygen carrier and blood substitute
This suit will distract us at a critical time when our attention should be focused on completion of the Biologics License Application for our PolyHeme oxygen-carrying blood substitute
product and submission of that application to the FDA.
OTCBB:SYBD) today announced that Oxycyte[TM], its proprietary perfluorocarbon (PFC) therapeutic oxygen carrier and blood substitute
, was featured in the November 2006 issue of Popular Science Magazine.
Nasdaq: NFLD), a leading developer of an oxygen-carrying blood substitute
, reported today that it has completed preparation of all of the components of its Biologics License Application (BLA), including collection and analysis of its clinical trial data for PolyHeme.
Investigators from the State University of New York at Buffalo (SUNY/UB) have demonstrated that the use of SONUS Pharmaceuticals' (Nasdaq: SNUS) blood substitute
product (S-9156), a perfluorocarbon-based emulsion, shows promise as a very efficient oxygen delivery vehicle at a dosage that is significantly less than other fluorocarbon-based oxygen carriers under development.